The use of elexacaftor/tezacaftor/ivacaftor in patients with cystic fibrosis postliver transplant: A case series-Reference-Cited by-同舟云学术

The use of elexacaftor/tezacaftor/ivacaftor in patients with cystic fibrosis postliver transplant: A case series

Author:

Ragan Hunter¹,Autry Elizabeth²³^ORCID,Bomersback Taryn⁴,Hewlett Jennifer⁵,Kormelink Lauren²³,Safirstein Julie⁶,Shanley Laura⁵,Lubsch Lisa¹⁷^ORCID

Affiliation:

1. Goldfarb School of Nursing at Barnes‐Jewish College St. Louis Missouri USA

2. Department of Pharmacy Services University of Kentucky HealthCare Lexington Kentucky USA

3. Department of Pharmacy Practice and Sciences University of Kentucky College of Pharmacy Lexington Kentucky USA

4. Alberta Health Services Calgary Alberta Canada

5. Children's Hospital of Philadelphia Philadelphia Pennsylvania USA

6. Hospital of the University of Pennsylvania Philadelphia Pennsylvania USA

7. SSM Cardinal Glennon Children's Hospital St. Louis Missouri USA

Publisher

Wiley

Subject

Pulmonary and Respiratory Medicine,Pediatrics, Perinatology and Child Health

Link

Reference7 articles.

1. Cystic Fibrosis Foundation Patient Registry.Annual data report;2019.

4. Trikafta (elexacaftor/tezacaftor/ivacaftor) [Package Insert]. Vertex Pharmaceuticals Inc.;2020.

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献